MedTrace Logo

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

NCT04972227 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-08-13

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen

Conditions

Interventions

DRUG

CY6463

oral tablets

DRUG

Placebo

oral tablets

Sponsors & Collaborators

  • Tisento Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jennifer Chickering · Cyclerion Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-10
Primary Completion
2022-04-18
Completion
2022-04-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04972227 on ClinicalTrials.gov